The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
Status:
Unknown status
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
RATIONAL: Preliminary results fron the Study MESOT-TREM-2012 indicate a promising activity of
tremelimumab in malignant mesothelioma (MM) patients.
PURPOSE: The proposed study MESOT-TREM-2012 aims to explore the efficacy of a more intensive
schedule of treatment with tremelimumab in 29 MM patients. Subjects will receive
investigational product every 4 weeks (wks) for 6 doses, followed by doses every 12 wks until
confirmed disease progression.